ProMIS Neurosciences Company Profile - aVenture Research
ProMIS Neurosciences
ProMIS Neurosciences is a clinical-stage biotechnology company whose EpiSelect platform computationally predicts and validates conformational epitopes.
ProMIS Neurosciences is a clinical-stage biotechnology company whose name, pronounced "Promise," derives from protein misfolding, the pathology behind many neurodegenerative diseases, and it runs a pipeline of clinical and preclinical antibody and vaccine candidates against these diseases for people living with neurodegenerative diseases. The company uses epitopes identified on misfolded proteins for direct vaccination to produce protective antibodies.
The EpiSelect platform integrates physics, biology and computational algorithms to predict and validate conformational epitopes, enabling discovery of epitopes unique to the disease state. Conventional methods using synthetic aggregates and linear peptides may identify targets not unique to the toxic form and produce antibodies with non-specific binding, which can reduce efficacy, trigger side effects and complicate dosing.